浓浓的年味尚未完全散去，位于连云港灌云经济开发区的江苏美特森切削工具有限公司已是一片繁忙的生产景象。从大年初四开始，这家公司以"开局就 是决战、起步就要冲刺"的干劲，在严格落实安全生产要求的前提下，全面吹响复工复产"集结号"，开足马力赶订单、忙生产，全力冲刺首季"开门红"。 走进该公司的生产车间，机器轰鸣，焊花四溅，自动化生产线高速运转。工人们在各自岗位上娴熟地操作设备，一件件精密的机械零部件在流水线上有序 传递，现场呈现出一派热火朝天、干劲十足的生产氛围。为保障节后顺利复工，公司提前部署，对生产设备进行了全面检修和维护，并对返岗员工进行了 安全生产培训，确保人员、设备以最佳状态投入生产。 该公司副总经理许其武告诉记者，他们公司大年初四就开始复工复产。在复产复工之前，做了节后的员工收心、安全培训以及设备的维护保养等相关工 作；目前订单在逐步增加，公司的产能也逐步恢复正常，正全力以赴冲刺首季开门红。 据了解，新的一年，该公司将继续聚焦主业，加大技术创新和产品研发力度，不断提升产品核心竞争力和市场占有率。公司将以"开局即冲刺"的奋斗姿 态，全力以赴保生产、拓市场、提效益，为圆满完成全年目标任务奠定坚实基础，也为灌 ...

报告期内，公司加强多元业务布局，在智能手机、汽车电子、智慧安防、机器视觉等领域持续深耕，加 强产品研发和市场推广，技术和产品创新促进了销售规模高速成长，人均创收持续增长，盈利能力大幅 提升，推动公司2025年度营业收入、营业利润、利润总额、归属于母公司所有者的净利润、归属于母公 司所有者的扣除非经常性损益的净利润、基本每股收益、加权平均净资产收益率实现大幅增长。同时， 报告期净利润增长，带动公司资产规模相应扩张。 智通财经APP讯，思特威(688213.SH)披露2025年年度业绩快报，报告期内，公司实现营业收入90.31亿 元，同比增加51.32%;实现归属于母公司所有者的净利润10.01亿元，同比增加154.97%。 ...

（来源：嘉兴日报） 转自：嘉兴日报 ■记者 吴晓慧 通讯员 章璟璟 仇立辉 昨天上午，位于南湖区大桥镇的浙江卫星新材料科技有限公司实验室内，一只表面皿中盛放着透明的液 体。"这是氨水，闻起来像厕所里那种刺鼻的味道。"企业副总经理马仲斌微微一笑，卖了个关子，"不 过别担心，只要加入我们的新产品，气味马上就会消失。" 研发团队"钻"了进去。从产品结构机理，到化学品官能团作用，一点点拆解。目前企业已研发生产十余 个大类的常规化产品及各类定制化产品，国内市场占有率约15%。 除了深耕研发，企业还将目光投向市场一线，挖掘客户需求。 企业前年在调研时发现一个痛点：卫生护理用品使用过程中，容易产生异味。基于此，企业决定研发缓 释性高吸收性树脂，既能控菌，也能除味。通俗来说，它通过物理吸附功能，把气味"吸"进通过特种工 艺处理的高分子材料中，同时释放出柠檬香味，增强抑菌作用。 方向有了，路却依然难走。 研发初期，仅"如何分解气味"这个问题，团队就进行了反复讨论。对企业而言，最大的挑战是如何让产 品功能既符合场景需求，又不产生化学品二次化学反应带来的使用风险。 最终历经一年半的时间，研发团队"另辟蹊径"，以物理方法规避二次化学 ...

Group 1: Financial Performance - Merck expects sales for 2026 to be between $65.5 billion and $67 billion, with adjusted earnings per share projected at $5.00 to $5.15, which is below Wall Street expectations due to one-time costs from the acquisition of Cidara Therapeutics [2] Group 2: Company Status - Keytruda's key patent is expected to gradually expire starting in 2028, with its growth showing signs of slowing down, as evidenced by 2025 sales of $31.7 billion, reflecting a 7% year-over-year increase [3] - Merck is in talks to acquire biotechnology company Revolution Medicines for a potential price of $28 billion to $32 billion, aiming to enhance its oncology pipeline with the experimental drug Daraxonrasib [4] - Sales of the HPV vaccine Gardasil declined by 39% year-over-year to $5.233 billion in 2025, impacted by decreased demand in China and updated vaccination guidelines in the U.S., necessitating ongoing monitoring of its recovery [6] Group 3: Product Development Progress - The pulmonary arterial hypertension drug Winrevair (sotatercept) achieved sales of $1.443 billion in 2025 and is expected to gain FDA approval for new indications in 2026, positioning it as a key product [5] - Oral PCSK9 inhibitor Enlicitide and other cardiovascular products are in late-stage development and may represent new growth opportunities [5]

2月7日消息，追觅科技创始人兼CEO俞浩连发两条微博回应"演唱会投入过多"质疑，俞浩表示，演唱会 几千万的投入，仅仅相当于公司一天的研发费用投入。追觅现在大约2万名研发管理人员，每天的研发 投入大概需要是4000万。他还透露，这两天在审批各个事业部递交过来的年终奖方案。主营业务，公司 把净利润的18%作为奖金发放。 "盈利最高的部门能拿到11个月的奖金，最高的个体预计会有20个月的奖金！年终奖的总奖金规模，会 达到10亿量级。" 以下为其微博原文： 有人说：把这么多钱花在演唱会上，不如好好花在产品研发上。那你是不知道我们在产品研发上投入了 多少。 演唱会几千万的投入，仅仅相当于我们公司一天的研发费用投入。追觅现在大约2万名研发管理人员， 每天的研发投入大概需要是4000万，你没看错，是每天。也就说，我每天一阵开眼，至少要有4000万花 在研发费用和员工工资上。 还有人说：不如把演唱会的花费，直接发给大家实在。正好这两天，我在审批各个事业部递交过来的年 终奖方案。主营业务，我们把净利润的18%作为了奖金发给了大家，这是很高的比例！因为我们今年的 主营业务的净利润是全行业最高的。这是纯现金部分，还没有算平时的任何 ...

Core Viewpoint - The company aims to enhance product research and market expansion by 2026 while implementing cost reduction and efficiency improvement measures to achieve profitability [2] Group 1 - The company plans to strengthen product development and market expansion efforts [2] - The company is committed to continuing its series of cost reduction and efficiency improvement measures [2] - The company aims to improve its operational status and achieve profitability as soon as possible [2]

锅圈（2517.HK）2025 年业绩预告点评 业绩兑现优秀，聚力共进迈步 2026 glmszqdatemark 相对走势 -10% 40% 90% 140% 2025/2 2025/8 2026/1 锅圈 恒生指数 相关研究 [盈利预测与财务指标 Table_Forcast] | 单位/百万人民币 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入 | 6,470 | 7,802 | 9,378 | 11,296 | | 增长率（%） | 6.2 | 20.6 | 20.2 | 20.5 | | 经调整净利润 | 311 | 463 | 589 | 728 | | 增长率（%） | 3.1 | 48.9 | 27.3 | 23.6 | | EPS(基于经调整净利润） | 0.11 | 0.17 | 0.21 | 0.27 | | P/E(基于经调整净利润） | 34 | 22 | 18 | 14 | | P/B | 3.3 | 3.1 | 2.8 | 2.5 | 资料来源：Wind，国联民生证券研究所预测（注：股 ...

Core Viewpoint - Changchun Gaoxin (000661.SZ) expects a significant decline in net profit attributable to shareholders for 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 150 million to 220 million yuan for 2025, indicating a substantial decline from the previous year [1] - The expected decline in profit is attributed to increased research and development expenses as the company advances its product pipeline [1] Group 2: Business Focus and Strategy - The company continues to focus on traditional strengths in endocrine metabolism and women's health, while also exploring innovative directions related to oncology, respiratory, and immune-related products [1] - Ongoing R&D efforts are aimed at developing differentiated products with global market potential, with several products entering clinical stages [1] Group 3: Industry Challenges - The company faces intensified competition within the industry, which is expected to impact its financial performance [1] - Changchun Baike Biotechnology Co., a subsidiary, is projected to incur losses in 2025, contributing to the overall decrease in the company's performance [1]

Core Viewpoint - Changchun Gaoxin has announced a significant decline in its expected net profit for 2025, projecting a decrease of 91.48% to 94.19% year-on-year, primarily due to increased R&D expenses and market challenges in the pharmaceutical industry [1] Group 1: Financial Projections - The company expects a net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of 91.48% to 94.19% [1] - The projected net profit after deducting non-recurring gains and losses is estimated to be between 437 million and 507 million yuan, reflecting a year-on-year decline of 82.09% to 84.56% [1] Group 2: Reasons for Profit Decline - Increased R&D expenses due to the company's focus on traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to oncology, respiratory, and immune diseases [1] - The launch of new products, including the first domestic innovative biological agent for acute gouty arthritis, has led to increased sales and marketing expenses, necessitating a market cultivation period for new products [1] - Adjustments in sales policies and pricing in response to industry policy changes and market conditions have resulted in reduced revenue and net profit [1] - The company’s subsidiary, Changchun Baike Biotechnology Co., is expected to incur losses in 2025, further impacting overall performance [1] Group 3: Licensing Agreement - The company’s subsidiary, Shanghai Saizeng Medical Technology Co., has entered into an exclusive licensing agreement for the GenSci098 injection project, which is expected to yield a total of $1.2 billion in upfront and milestone payments [1] - The agreement includes a non-refundable upfront payment of $70 million and an additional $50 million in milestone payments, with potential for up to $1.365 billion in further milestone payments and over 10% in sales royalties post-product launch [1] - The financial impact of this licensing agreement will not be reflected in the current reporting period due to accounting policy requirements [1]

Core Viewpoint - Shenzhou Cell (688520.SH) is expected to report a significant net loss for the year 2025, with projected losses ranging from -5.8 billion to -5.2 billion yuan, primarily due to declining sales and increased commercialization costs [1] Financial Performance - The net profit attributable to the parent company is forecasted to be between -5.8 billion and -5.2 billion yuan for 2025 [1] - The net profit after deducting non-recurring gains and losses is expected to be between -5.63 billion and -5.03 billion yuan [1] - Research and development expenditures for 2025 are projected to be between 830 million and 870 million yuan [1] Reasons for Performance Change - The decline in sales revenue is attributed to the ongoing tightening of healthcare cost control policies and significant price reductions of the core product, Anjia [1] - Increased upfront commercialization investments, including academic promotion and sales team formation, have led to a noticeable rise in sales expenses [1] - The company continues to pursue a multi-product pipeline strategy, with several projects entering critical confirmatory clinical trial phases, maintaining high levels of R&D investment, which has impacted current profitability [1]